Scinai Immunotherapeutics Statistics
Total Valuation
SCNI has a market cap or net worth of $1.21 million. The enterprise value is $2.14 million.
| Market Cap | 1.21M |
| Enterprise Value | 2.14M |
Important Dates
The next estimated earnings date is Friday, August 28, 2026, after market close.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SCNI has 395,979 shares outstanding. The number of shares has increased by 140.86% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 395,979 |
| Shares Change (YoY) | +140.86% |
| Shares Change (QoQ) | +23.00% |
| Owned by Insiders (%) | 20.53% |
| Owned by Institutions (%) | 5.20% |
| Float | 314,683 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.86 |
| Forward PS | n/a |
| PB Ratio | 0.19 |
| P/TBV Ratio | 0.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.56 |
| Quick Ratio | 1.22 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.54 |
Financial Efficiency
Return on equity (ROE) is -26.53% and return on invested capital (ROIC) is -41.10%.
| Return on Equity (ROE) | -26.53% |
| Return on Assets (ROA) | -36.15% |
| Return on Invested Capital (ROIC) | -41.10% |
| Return on Capital Employed (ROCE) | -56.16% |
| Weighted Average Cost of Capital (WACC) | 7.42% |
| Revenue Per Employee | $33,044 |
| Profits Per Employee | -$57,756 |
| Employee Count | 45 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.06% in the last 52 weeks. The beta is 2.09, so SCNI's price volatility has been higher than the market average.
| Beta (5Y) | 2.09 |
| 52-Week Price Change | -81.06% |
| 50-Day Moving Average | 2.68 |
| 200-Day Moving Average | 6.36 |
| Relative Strength Index (RSI) | 59.47 |
| Average Volume (20 Days) | 79,759 |
Short Selling Information
The latest short interest is 46,462, so 0.09% of the outstanding shares have been sold short.
| Short Interest | 46,462 |
| Short Previous Month | 455,184 |
| Short % of Shares Out | 0.09% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.09 |
Income Statement
In the last 12 months, SCNI had revenue of $1.49 million and -$2.60 million in losses. Loss per share was -$4.89.
| Revenue | 1.49M |
| Gross Profit | -3.75M |
| Operating Income | -8.39M |
| Pretax Income | -2.60M |
| Net Income | -2.60M |
| EBITDA | -6.64M |
| EBIT | -8.39M |
| Loss Per Share | -$4.89 |
Balance Sheet
The company has $2.65 million in cash and $3.58 million in debt, with a net cash position of -$926,000 or -$2.34 per share.
| Cash & Cash Equivalents | 2.65M |
| Total Debt | 3.58M |
| Net Cash | -926,000 |
| Net Cash Per Share | -$2.34 |
| Equity (Book Value) | 11.73M |
| Book Value Per Share | 10.71 |
| Working Capital | 1.26M |
Cash Flow
In the last 12 months, operating cash flow was -$6.45 million and capital expenditures -$18,000, giving a free cash flow of -$6.46 million.
| Operating Cash Flow | -6.45M |
| Capital Expenditures | -18,000 |
| Depreciation & Amortization | 1.52M |
| Net Borrowing | n/a |
| Free Cash Flow | -6.46M |
| FCF Per Share | -$16.32 |
Margins
Gross margin is -252.32%, with operating and profit margins of -564.36% and -174.78%.
| Gross Margin | -252.32% |
| Operating Margin | -564.36% |
| Pretax Margin | -174.78% |
| Profit Margin | -174.78% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SCNI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -140.86% |
| Shareholder Yield | -140.86% |
| Earnings Yield | -203.83% |
| FCF Yield | -506.96% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 118.93% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 21, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Aug 21, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |